{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 175,
  "pageCount": 239,
  "prevPage": 174,
  "nextPage": 176,
  "slideType": "testimonial",
  "function": "illustrate_case",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses expert testimony to frame the company's situation as dire.",
  "elementsJson": [
    "headline_text",
    "subtitle_text",
    "bullet_list",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/175",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-175",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The only reason why Grossman stabilized the salesforce was because the stock price went up and those reps had options.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-ace019741318",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.06,
        "y": 0.19
      },
      "kind": "list",
      "text": "The ex-executive stated Nevro will now “die of a thousand cuts” and provided a damning assessment: no growth from Omnia; losing doctors; no market share gains; and being forced to pay doctors to use the product.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d7c2e37b-2100-4469-980a-a6b6987f70f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.06,
        "y": 0.45
      },
      "kind": "list",
      "text": "He stated that there will be an exodus of sales reps at the end of this year – “a bloodletting” - when options expire, and that reps are ready to flee to new competitors such as Saluda",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dff016af-4ebe-46cf-9103-2db42fab7e2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "The former executive described a dire situation at Nevro with an impending exodus of talent.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cce0572-5f00-46de-9b8a-bb45bd6f2e41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.85,
        "x": 0.1,
        "y": 0.52
      },
      "kind": "quote",
      "text": "“The only reason why Grossman stabilized the salesforce was because the stock price went up and those reps had options... Interesting enough, most all those options are going to expire at the end of this year and its going to be a bloodletting. All those reps are going to leave... It’s kind of a rinse and wash type philosophy.” – Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40be16d7-35aa-48a0-aac8-d057f751ba6d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.1,
        "y": 0.26
      },
      "kind": "quote",
      "text": "“Nevro has boxed themselves into a corner and now they’ll die of a thousand cuts. because unless they start seeing some increased sales, which they’re not going to at the price point that they’re at... Who are they converting from Boston, from Medtronic, from Abbott? Where are those customers? And you don’t see it.” – Former Nevro executive",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f2a19056-132b-47a8-a386-cfc4f1beaeb2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"Nevro has boxed themselves into a corner and now they’ll die of a thousand cuts. because unless they start seeing some increased sales, which they’re not going to at the price point that they’re at, because the high-volume doctors are not going to overpay for Omnia. Maybe the diehard Nevro guys hold on, but how many of those diehard guys are also consultants for the company? How many new customers are they getting? Who are they converting from Boston, from Medtronic, from Abbott? Where are those customers? And you don’t see it.\" — Former Nevro executive; \"The only reason why Grossman stabilized the salesforce was because the stock price went up and those reps had options. Those options were in general in the high 60’s...that’s $200,000-$300,000 to those reps, so they’re going to stay. Interesting enough, most all those options are going to expire at the end of this year and its going to be a bloodletting. All those reps are going to leave, because they want to get out of their non-competes and then in a year they go back into the Saluda’s, the Nalu’s and everything else. It’s kind of a rinse and wash type philosophy. If the price of the stock goes down, you’ll see a major amount of reps leave the company, and they’ll go elsewhere.\" — Former Nevro executive",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b345-b24025a4f11d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f88cf74b-bce0-411f-bd3f-947e2eac6eff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "12. Investors betting on a Keith Grossman-driven turnaround will shortly face a rude awakening",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "86430757-5421-4b2e-979c-0262cb7f21c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2eb6deb9-cb3c-42e4-9293-a6dafef1867d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "5473a988-0fa6-4b25-ad86-ff7d54e9caf8",
      "evidence": "The slide uses a clear, thesis-driven headline to frame the argument.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}